Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sandoz Group Ltd ( (CH:SDZ) ) has provided an announcement.
Sandoz plans to leverage its status as the leading pure‑play biosimilar and generics manufacturer to capture a substantial share of an expected USD 600 billion wave of patent expiries over the next decade. Speaking at the J.P. Morgan Healthcare Conference, CEO Richard Saynor will outline how recent strategic investments in European manufacturing hubs in Slovenia and France, successful biosimilar and generic launches, and a pipeline of more than 400 assets position the company to target roughly two‑thirds of the global generic and about 60% of the biosimilar loss‑of‑exclusivity opportunity, particularly in oral solids, injectables and longer‑term GLP‑1 therapies. Backed by 2024 sales of USD 10 billion and ongoing margin expansion, Sandoz aims to turn this “golden decade” of affordable medicines into accelerated growth and broader patient access, reinforcing its leadership in a market that already accounts for most prescriptions but a minority of total drug spending, and potentially reshaping competitive dynamics and cost pressures across global healthcare systems.
The most recent analyst rating on (CH:SDZ) stock is a Buy with a CHF70.00 price target. To see the full list of analyst forecasts on Sandoz Group Ltd stock, see the CH:SDZ Stock Forecast page.
More about Sandoz Group Ltd
Sandoz Group AG, headquartered in Basel, Switzerland, is a global leader in affordable medicines, focused exclusively on biosimilars and generic drugs. With a portfolio of around 1,300 products spanning conditions from common colds to cancer, the company supplies treatments to roughly 900 million patients annually and operates in more than 100 countries. Since becoming an independent, pure‑play generics and biosimilars company in 2023, Sandoz has built its scale on a broad manufacturing and supply network, particularly in Europe, and reported net sales of about USD 10.4 billion in 2024, driven by strong growth in biosimilars.
YTD Price Performance: 4.70%
Average Trading Volume: 723,495
Technical Sentiment Signal: Buy
Current Market Cap: CHF26.65B
For an in-depth examination of SDZ stock, go to TipRanks’ Overview page.